Abstract
Fulminant myocarditis may be complicated with various degrees of conduction block, ventricular premature, ventricular tachycardia, ventricular fibrillation or even electric storm. These arrhythmias may further aggravate the severity of disease via affecting stability of hemodynamics, and in turn, instability of hemodynamics as well as hypopotassemia is risk factor of arrhythmias. Therefore, it is necessary to strengthen dynamic monitoring of blood pressure, electrolyte and QT interval, actively deal with hypotension and shock, and maintain electrolyte, especially blood potassium, at a high level. For bradyarrhythmias, we can consider the use of heart rate increasing drugs and pacing therapy. Ventricular tachycardia can be treated with lidocaine, amiodarone, nificaran, or other drugs according to the situation, and electrocardioversion should be used when necessary.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Ma M, Hui J. Progress in the treatment of severe fulminant myocarditis. J Clin Cardiol. 2010;26:83–6.
Li Y, Sun L, Guo L. Status and progress of diagnosis and treatment of fulminant myocarditis. Natl Med J China. 2017;97:235–7.
The Precision Medicine Group of Chinese Society of Cardiology, the Editorial Board of Chinese Journal of Cardiology, the Working Group on Adult Fulminant Myocarditis. Chinese expert consensus on the diagnosis and treatment of adult fulminant myocarditis. Chin J Cardiol. 2017;45:742–52.
Epstein AE, Dimarco JP, Ellenbogen KA, Estes NA 3rd, Freedman RA, Gettes LS, Gillinov AM, Gregoratos G, Hammill SC, Hayes DL, et al. ACC/AHA/HRS 2008 Guidelines for device-based therapy of cardiac rhythm abnormalities. Heart Rhythm. 2008;5:e1–62. https://doi.org/10.1016/j.hrthm.2008.04.014.
Guo P, Qiu J, Wang Y, Chen G, Proietti R, Fadhle AS, Zhao C, Wen WD. Zero-fluoroscopy permanent pacemaker implantation using Ensite NavX system: clinical viability or fanciful technique? Pacing Clin Electrophysiol. 2018;41:122–7. https://doi.org/10.1111/pace.13248.
Chaudhry-Waterman N, Kumar V, Karr S, Fitzpatrick A, Cohen MI. Challenge of managing opposing rhythms in a mother and fetus. Pacing Clin Electrophysiol. 2021;44:373–7. https://doi.org/10.1111/pace.14059.
Huu AL, Shum-Tim D. Intra-aortic balloon pump: current evidence & future perspectives. Futur Cardiol. 2018;14:319–28. https://doi.org/10.2217/fca-2017-0070.
Maciąg A, Syska P, Oręziak A, Przybylski A, Broy B, Kołsut P, Zając D, Bilińska M, Sterliński M, Szwed H. Long-term temporary pacing with an active fixation lead. Kardiol Pol. 2015;73:1304–9. https://doi.org/10.5603/KP.a2015.0093.
Goncalves CR, Bertog S, Tholakanahalli V, Römer A, Hofmann I, Reinartz M, Gafoor S, Sievert K, Schnelle N, Grunwald I, et al. Permanent pacemaker lead insertion connected to an external pacemaker generator for temporary pacing after transcatheter aortic valve implantation. Cardiovasc Revasc Med. 2020;21(6):726–9. https://doi.org/10.1016/j.carrev.2020.02.002.
Zipes DP, Camm AJ, Borggrefe M, Buxton AE, Chaitman B, Fromer M, Gregoratos G, Klein G, Moss AJ, Myerburg RJ, et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for practice guidelines (writing committee to develop guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation. 2006;114:e385–484. https://doi.org/10.1161/CIRCULATIONAHA.106.178233.
Cao K, Chen K, Chen M. 2020 Chinese expert consensus on ventricular arrhythmia (2016 consensus upgrade). Chin J Cardiac Pacing Electrophysiol. 2020;34:189–253.
Guo M, Tian S, Song Y. The clinical application of Nificaran. J Clin Cardiol. 2017;33:188–90.
Hu J, Yu J, Chen Q, Hu J, Huang Q, Xia Z, Xia Z, Ju Z, Yuan P, Fan S, et al. Efficacy of nifekalant in patients with wolff-parkinson-white syndrome and atrial fibrillation: electrophysiological and clinical findings. J Am Heart Assoc. 2019;8:e012511. https://doi.org/10.1161/JAHA.119.012511.
Zhang J, Zan Y, Huo H, Liu Y, Tang Y, Han Y. Population pharmacokinetic/pharmacodynamic modelling of nifekalant in healthy Chinese volunteers. Eur J Pharm Sci. 2020;151:105385. https://doi.org/10.1016/j.ejps.2020.105385.
Pantazopoulos IN, Troupis GT, Pantazopoulos CN, Xanthos TT. Nifekalant in the treatment of life-threatening ventricular tachyarrhythmias. World J Cardiol. 2011;3(6):169–76.
The Chinese Society of Critical Care Medicine. Guidelines for analgesia and sedation treatment in adult ICU in China. Chin Crit Care Med. 2018;30(6):497–514.
China Hubei Green Electrophysiology Alliance, Wuhan Medical Association Electrophysiology and Pacing Branch. Key points and understanding of perioperative management of radiofrequency catheter ablation for atrial fibrillation. J Clin Intern Med. 2020;37:743–6.
Garnock-Jones KP. Esmolol: a review of its use in the short-term treatment of tachyarrhythmias and the short-term control of tachycardia and hypertension. Drugs. 2012;72:109–32. https://doi.org/10.2165/11208210-000000000-00000.
Liu P, Wu Q, Tang Y, Zhou Z, Feng M. The influence of esmolol on septic shock and sepsis: a meta-analysis of randomized controlled studies. Am J Emerg Med. 2018;36:470–4. https://doi.org/10.1016/j.ajem.2017.11.013.
El-Sherif N, Turitto G, Boutjdir M. Congenital Long QT syndrome and torsade de pointes. Ann Noninvasive Electrocardiol. 2017;22:e12481. https://doi.org/10.1111/anec.12481.
Huang C, Zhang S, Huang D. Atrial fibrillation: current understanding and treatment recommendations—2018. Chin J Cardiac Pacing Electrophysiol. 2018;32:315–68.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2022 The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Wang, Y. (2022). Prevention and Treatment of Arrhythmias Complicated by Fulminant Myocarditis. In: Wang, D.W. (eds) Fulminant Myocarditis. Springer, Singapore. https://doi.org/10.1007/978-981-19-5759-8_16
Download citation
DOI: https://doi.org/10.1007/978-981-19-5759-8_16
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-19-5758-1
Online ISBN: 978-981-19-5759-8
eBook Packages: MedicineMedicine (R0)